NewsMeter
$2.8 billion is what Eli Lilly has agreed to pay for AtaiBeckley, a maker of experimental psychedelic-based drugs.
The deal hands Lilly a pipeline built on DMT and MDMA, two compounds drawing growing pharmaceutical attention. The acquisition arrives as experimental treatments in this category gain traction.
What the price buys AtaiBeckley develops experimental drugs based on DMT (dimethyltryptamine) and MDMA (methylenedioxymethamphetamine). Both are psychedelic compounds.
Neither has a standard approved therapeutic application at the time of the announcement. Lilly's $2.8 billion is a pre-commercialization commitment to programs built around these molecules.
Keep reading